Diabetic Nephropathy

Data show FG-3019 improves kidney function in late-stage disease model

Published in Drug Week, December 3rd, 2004

FibroGen, Inc., announced that FG-3019, the company's lead investigational antifibrotic agent, significantly improved glomerular filtration rate (a measure of kidney function) and reduced proteinuria (abnormal presence of protein in the urine) in a preclinical model of overt diabetic nephropathy (DN).

The data support the therapeutic potential of FG-3019 in treating DN by inhibiting fibrosis, or excessive and persistent scarring, which ultimately causes kidney failure.

FG-3019 is a fully human monoclonal antibody designed to inhibit the fibrotic activity of connective tissue growth factor (CTGF). These results were part of multiple abstracts...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-12-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry